Bausch & Lomb is one of the largest vision care companies in the US. Bausch spun off from its former parent company, Bausch Health, in 2022 and it now operates in three segments: vision care, surgical ...

Vision Care revenue increased by 5%, driven by Daily SiHy lenses (up 42%) and Blink products (up 85%). The Surgical segment grew by 11%, led by premium IOLs (up 77%), while Pharmaceuticals posted 1% ...

Bausch + Lomb Corporation ( NYSE: BLCO) Q1 2025 Earnings Conference Call April 30, 2025 8:00 AM ET George Gadkowski - Vice President, Investor Relations & Business Insights Brent Saunders - Chairman & ...

EPS, expectations were $0.03. Operator: Good morning, and welcome to Bausch + Lomb’s First Quarter 2025 Earnings Call. All participants will be in listen-only mode. [Operator Instructions] Please note ...

Bausch & Lomb Corp (BLCO) reports steady revenue growth and strategic resilience despite facing headwinds from recalls and tariffs.

Bausch + Lomb, a leading global eye health company, announced a voluntary recall of its Envista Aspire, Envista Envy and certain Envistar intraocular lens injector systems, according to the Food ...

Bausch + Lomb (NYSE:BLCO ... the company’s Infuse daily silicone hydrogel lenses delivered 42% constant currency revenue growth in Q1 2025, with 56% growth in the U.S. and 23% growth ...

Bausch + Lomb’s Vision Care segment, its largest by revenue, grew 3% to $656 million, driven by increased sales of daily contact lenses and over-the-counter eye care products. The Surgical ...

Bausch + Lomb (NYSE:BLCO) reported mixed first quarter 2025 ... In the contact lens segment, the company’s Infuse daily silicone hydrogel lenses delivered 42% constant currency revenue growth in Q1 ...